欧美日韩电影国产一区二区,园产精品一区二区三区,欧美成人精品第一区二区三区,久久精品国产久精国产,日本精品免费一区二区三区,国产一区二区三区三级高清,精品国产乱码久久久紫薇蜜桃,国产精品一区二区小说

History

2007,

2007,Klox was founded.







2013,

Initial Launch Of Kleresca.










2016,










2019,

Received the 2019 Innovation Award at the Targeting Mitochondria Congress.










2007,

Klox was founded.

2011,

First FLE Biomodulation patent issued.

2013,

Received CE mark approval in Europe and Canadian approval for Kleresca.

2014,

Received CE mark approval in Europe for LumiHeal for the treatment of chronic and acute wounds.

2015,

Received CE mark approval in Europe for Perio-1, an adjunct treatment for periodontitis.

2016,

Initial launch of Kleresca.

2017,

Initial launch of LumiHeal.

2018,

Topline results presented at the European Wound Management Association (EWMA) for the treatment of chronic wounds. Plans to conduct U.S. 510(k) clinical trials for chronic wounds

2019,

Received the 2019 Innovation Award at the Targeting Mitochondria Congress.

2020,

KloxAsia headquarter was established in Hong Kong, the R & D center is in Guangzhou, China; LumiHeal and Kleresca have been classified as class III and Class II medical devices respectively, and will soon receive FDA approval.

2021,

Received NMPA approval in China for LumiHeal and Kleresca.